Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NOVONIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NOVONIX's regulatory disclosures and financial reporting.
Novonix Limited filed a Form 6-K as a foreign private issuer for December 2025. The filing mainly forwards an exhibit, Appendix 2A, which is an application for quotation of securities dated December 18, 2025. The report is signed by the Chief Financial Officer, Robert Long.
Novonix Limited has reported a change in its board of directors. The company submitted a report to U.S. regulators highlighting an attached announcement from the Australian Securities Exchange.
The exhibit notes the appointment of Mike O'Kronley to the Board of Directors, dated December 15, 2025. This update formally records the new board role for investors who follow Novonix through U.S. markets.